Your session is about to expire
← Back to Search
DS-3201b for Lymphoma
Study Summary
This trial is currently enrolling in the US, South Korea, and Taiwan.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition did not improve with standard treatment or there is no standard treatment available.I have been diagnosed with a specific type of skin or blood cancer.I have taken certain medications that affect liver enzymes or heart medication in the last 14 days.I am willing to give a fresh tissue sample at the end of my treatment.My ATL is acute, lymphomatous, or chronic with a poor outlook.My cancer came back or didn't respond after at least 1 treatment.I am fully active or can carry out light work.I am willing to provide tissue samples from my tumor for testing.My cancer came back or didn't respond after at least 1 treatment.My organ functions are normal according to my recent tests.I do not have any serious health or mental conditions that could worsen by joining this study.I have not taken any drugs or treatments that the study does not allow.I have been treated with EZH inhibitors before.I had a stem cell transplant from a donor within the last 3 months.I have been diagnosed with non-Hodgkin's lymphoma.I am willing to provide tissue samples from my tumor for testing.I am legally an adult in my country.My organ functions are normal according to my recent tests.I am willing to give a fresh tissue sample at the end of my treatment.My ATL is acute, lymphomatous, or chronic with a poor outlook.My cancer has spread to my brain or spinal cord.My condition did not improve with standard treatment or there is no standard treatment available.I have been diagnosed with non-Hodgkin's lymphoma.I am legally an adult in my country.I am fully active or restricted in physically strenuous activity but can do light work.
- Group 1: DS-3201b
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA given its seal of approval to DS-3201b?
"Due to the lack of safety and efficacy data in Phase 1 trials, we assign a score of 1 out of 3 for DS-3201b's safety profile."
How many geographical sites are actively conducting this research?
"This experiment is currently being conducted at 10 locations across the nation, including Atlanta, New york City and Columbus. It would behoove those interested in participating to select a nearby site so as to reduce travel demands."
Have you opened recruitment for this trial yet?
"The analysis of clinicaltrials.gov states that this particular medical trial is no longer looking to recruit patients, having last been updated on August 30th 2022 after being initially posted on March 31st 2016. Notwithstanding, there are 1726 other studies actively searching for participants at the current time."
What are the desired outcomes of this research endeavor?
"This clinical trial seeks to evaluate the Average plasma concentration (Cavg) over a 28-day cycle. Secondary endpoints include assessing responses from participants with CTCL and malignant lymphoma using 2011 CTCL criteria, international consensus standards, and objective response rate measures."
Share this study with friends
Copy Link
Messenger